Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altamira Therapeutics Ltd (NQ: CYTO )

2.860 -0.060 (-2.05%)
Streaming Delayed Price Updated: 3:59 PM EST, Feb 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,670
Open 2.890
Bid (Size) 2.860 (1)
Ask (Size) 3.180 (2)
Prev. Close 2.920
Today's Range 2.810 - 2.980
52wk Range 2.700 - 43.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Altamira Therapeutics to Present at Two Upcoming RNA Therapeutics Conferences in Q1 2023
Via ACCESSWIRE
Dow Gains Over 100 Points; Eastern Bankshares Shares Drop After Q4 Results
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 1% on Friday. The Dow traded up 0.41% to 34,088.68 while the NASDAQ rose 1.27% to 11,659.16. The S&P 500... 
Via Benzinga

Performance

YTD
-45.00%
-45.00%
1 Month
-47.13%
-47.13%
3 Month
-50.52%
-50.52%
6 Month
-69.57%
-69.57%
1 Year
-88.91%
-88.91%

More News

Read More
Why Applied UV Shares Are Trading Higher By 46%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
US Stocks Higher; Dow Rises 150 Points
Via Benzinga
Altamira Therapeutics Provides Business Update
From Altamira Therapeutics Ltd
Via Globe NewsWire
Dow Rises 80 Points; Altamira Therapeutics Shares Plunge
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Dow Drops 100 Points; Verizon Issues Weak Earnings Forecast
Via Benzinga
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
From Altamira Therapeutics Ltd
Via Globe NewsWire
Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th
From Altamira Therapeutics Ltd
Via Globe NewsWire
Altamira Therapeutics Provides Year-End 2022 Business Update
From Altamira Therapeutics Ltd
Via Globe NewsWire
Altamira Therapeutics Reaches Midpoint for Enrollment in Clinical Trial with Bentrio in Seasonal Allergic Rhinitis in Australia
Via ACCESSWIRE
Altamira Therapeutics Provides Business Update and First Half 2022 Financial Results
From Altamira Therapeutics Ltd
Via Globe NewsWire
Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma
From Altamira Therapeutics Ltd
Via Globe NewsWire
In Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque Stability
Via ACCESSWIRE
Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid Event
From Altamira Therapeutics Ltd
Via Globe NewsWire
Altamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid Requirement
From Altamira Therapeutics Ltd
Via Globe NewsWire
Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamira’s Bentrio under Controlled Grass Pollen Exposure
From Altamira Therapeutics Ltd
Via Globe NewsWire
Altamira Therapeutics Announces Reverse Stock Split
From Altamira Therapeutics Ltd
Via Globe NewsWire
Why Tricida Shares Dipped Around 95%; Here Are 73 Biggest Movers From Yesterday
Via Benzinga
Dow Jumps 650 Points; Gold Rises Over 1%
Via Benzinga
Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday
Via Benzinga
Why Boston Beer Shares Are Trading Higher? Here Are 52 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.